Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Page 1
Model-Informed Precision Dosing Guidance of Ethosuximide Developed from a Randomized Controlled Clinical Trial of Childhood Absence Epilepsy.
Mizuno K, Capparelli EV, Fukuda T, Dong M, Adamson PC, Blumer JL, Cnaan A, Clark PO, Reed MD, Shinnar S, Vinks AA, Glauser TA; Childhood Absence Epilepsy Study Group. Mizuno K, et al. Among authors: blumer jl. Clin Pharmacol Ther. 2023 Aug;114(2):459-469. doi: 10.1002/cpt.2965. Epub 2023 Jun 25. Clin Pharmacol Ther. 2023. PMID: 37316457 Clinical Trial.
However, 47% of ethosuximide initial monotherapy participants experienced short-term treatment failure. This study aimed to characterize the initial monotherapy ethosuximide exposure-response relationship and to propose model-informed precision dosing guidance. ...
However, 47% of ethosuximide initial monotherapy participants experienced short-term treatment failure. This study aimed to character …
Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders.
Noel GJ, Bradley JS, Kauffman RE, Duffy CM, Gerbino PG, Arguedas A, Bagchi P, Balis DA, Blumer JL. Noel GJ, et al. Among authors: blumer jl. Pediatr Infect Dis J. 2007 Oct;26(10):879-91. doi: 10.1097/INF.0b013e3180cbd382. Pediatr Infect Dis J. 2007. PMID: 17901792 Clinical Trial.
METHODS: Safety data were collected in children who participated in 1 of 3 efficacy trials (N = 2523) and a subset of these children who also subsequently participated in a long-term 1-year surveillance trial (N = 2233). Incidence of adverse events in children randomized t …
METHODS: Safety data were collected in children who participated in 1 of 3 efficacy trials (N = 2523) and a subset of these children who als …
Comparative effects of single-dose ceftriaxone versus three oral antibiotic regimens on stool colonization by resistant bacilli in children.
Toltzis P, Dul M, O'Riordan MA, Toltzis H, Blumer JL. Toltzis P, et al. Among authors: blumer jl. Pediatr Infect Dis J. 2007 Jan;26(1):25-30. doi: 10.1097/01.inf.0000247130.11902.64. Pediatr Infect Dis J. 2007. PMID: 17195701 Clinical Trial.
OBJECTIVE: The use of short-term intramuscular ceftriaxone for pediatric ambulatory conditions raises concerns regarding the promotion of resistance among colonizing enteric bacteria. ...
OBJECTIVE: The use of short-term intramuscular ceftriaxone for pediatric ambulatory conditions raises concerns regarding the promotio …
Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.
Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, Leitz GJ, Territo MC. Winston DJ, et al. Among authors: blumer jl. Ann Intern Med. 2003 May 6;138(9):705-13. doi: 10.7326/0003-4819-138-9-200305060-00006. Ann Intern Med. 2003. PMID: 12729424 Clinical Trial.
OBJECTIVE: To compare the efficacy and safety of intravenous and oral itraconazole with the efficacy and safety of intravenous and oral fluconazole for long-term prophylaxis of fungal infections. DESIGN: Open-label, multicenter, randomized trial. ...CONCLUSION: Itraconazol …
OBJECTIVE: To compare the efficacy and safety of intravenous and oral itraconazole with the efficacy and safety of intravenous and oral fluc …
Cefotaxime-resistant bacteria colonizing older people admitted to an acute care hospital.
Bonomo RA, Donskey CJ, Blumer JL, Hujer AM, Hoyenm CK, Jacobs MR, Whalen CC, Salata RA. Bonomo RA, et al. Among authors: blumer jl. J Am Geriatr Soc. 2003 Apr;51(4):519-22. doi: 10.1046/j.1532-5415.2003.51161.x. J Am Geriatr Soc. 2003. PMID: 12657072 Free PMC article.
OBJECTIVES: To determine the frequency of fecal colonization by cefotaxime-resistant gram-negative bacilli in older patients living in the community and in long-term care facilities (LTCFs) admitted to an acute care hospital. ...
OBJECTIVES: To determine the frequency of fecal colonization by cefotaxime-resistant gram-negative bacilli in older patients living in the c …
Paroxetine pharmacokinetics in depressed children and adolescents.
Findling RL, Reed MD, Myers C, O'Riordan MA, Fiala S, Branicky L, Waldorf B, Blumer JL. Findling RL, et al. Among authors: blumer jl. J Am Acad Child Adolesc Psychiatry. 1999 Aug;38(8):952-9. doi: 10.1097/00004583-199908000-00010. J Am Acad Child Adolesc Psychiatry. 1999. PMID: 10434486
CONCLUSIONS: Paroxetine is more rapidly cleared in youths than adults and may be given once daily in this population. Short-term treatment with paroxetine appears safe and well tolerated in this relatively small sample of pediatric patients....
CONCLUSIONS: Paroxetine is more rapidly cleared in youths than adults and may be given once daily in this population. Short-term trea …
Pharmacology of new hormonal therapies in the treatment of pediatric endocrine disorders.
Usala AL, Blumer JL. Usala AL, et al. Among authors: blumer jl. Pediatr Clin North Am. 1989 Oct;36(5):1157-82. doi: 10.1016/s0031-3955(16)36763-3. Pediatr Clin North Am. 1989. PMID: 2571972 Review.
The clinician must evaluate potential risks and benefits as these substances come to market without definitive answers being available as to their long-term effects....
The clinician must evaluate potential risks and benefits as these substances come to market without definitive answers being available as to …
Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I).
Besunder JB, Reed MD, Blumer JL. Besunder JB, et al. Among authors: blumer jl. Clin Pharmacokinet. 1988 Apr;14(4):189-216. doi: 10.2165/00003088-198814040-00001. Clin Pharmacokinet. 1988. PMID: 3292100 Review.
Certain biotransformation pathways, including hydroxylation by the P450 mono-oxygenase system and glucuronidation, demonstrate only limited activity at birth, while other pathways, such as sulphate or glycine conjugation, appear very efficient at birth. ...The glome …
Certain biotransformation pathways, including hydroxylation by the P450 mono-oxygenase system and glucuronidation, demonstrate only limited …
Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis.
Reed MD, Stern RC, Bertino JS Jr, Myers CM, Yamashita TS, Blumer JL. Reed MD, et al. Among authors: blumer jl. J Pediatr. 1984 Feb;104(2):303-7. doi: 10.1016/s0022-3476(84)81019-7. J Pediatr. 1984. PMID: 6607329
The area under the SMZ serum concentration-time curve was significantly greater at steady state, suggesting drug accumulation during long-term therapy. When pharmacokinetic characteristics for TMP and SMZ obtained in patients with cystic fibrosis were compared with those r …
The area under the SMZ serum concentration-time curve was significantly greater at steady state, suggesting drug accumulation during long- …
11 results